To view the lectures marked MULTIMEDIA, you will require Macromedia Flash Player 4 or later. Also, to view QuickTime videos in the lectures, you will require QuickTime Player 4.1 or later. Macromedia Flash Player and QuickTime Player are available at http://www.macromedia.com and http://www.apple.com respectively.

	The Way Forward: High-Dose, Short-Course Levofloxacin Leads the Field (Interview with Prof. Lala M. Dunbar, MD, PhD ) NEW!
	The Role of 750 mg Once-Daily Levofloxacin in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Diseases (Interview with Prof. Ronald F. Grossman, MD, FRCPC, FCCP, FACP )
	The Efficacy, Tolerability, and Benefits of 750 mg Once-Daily Levofloxacin in the Treatment of Community-Acquired Pneumonia (Interview with Prof. Thomas M. File, Jr, MD, MS )
	Levofloxacin for the Management of Hospital-Acquired, Ventilator-Associated and Healthcare-Associated Pneumonia (Interview with Prof. Marin H. Kollef)
	The Use of Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis (Interview with Prof. Hartmut Lode)
	New Insights in the Treatment of Severe Infections in the Multiple-Drug Resistant Situation (Highlights of the Daiichi Pharmaceutical Co., Ltd. Satellite Symposium to the 11th International Congress on Infectious Diseases)
	Levofloxacin Stands Above the Rest: A Fluoroquinolone with Both Efficacy and Safety (Highlights of a Special Roundtable Discussion)
	Levofloxacin in the Medical Management of Community-acquired Pneumonia (Interview with Prof. Andy I. M. Hoepelman)
	New Challenges for Levofloxacin in the Fight Against Infectious Diseases (Interviews with World-Renowned Experts)

New Era for the Treatment of Respiratory Tract infections (Daiichi Pharmaceutical Co., Ltd., Special Interview)

Safety Assessment of Antimicrobial Agents: Criteria for the Balance Between Efficacy and Safety (Aventis Pharma/Daiichi Pharmaceutical Co. Ltd./ Ortho-McNeil Pharmaceutical Inc. Joint-Sponsored Symposium At the 22nd International Congress of Chemotherapy)

Defining the Appropriate Critical Pathway for the Treatment of Infectious Diseases: Challenging Drug-Resistant Pathogens (Highlights of a Special Roundtable Discussion)

Quinolones Are Not All the Same: Different Safety Profiles for Specific Compounds (Highlights of a Special Roundtable Discussion)

The Role of Levofloxacin for the Treatment of Respiratory Tract Infections (Highlights of a Special Roundtable Discussion)